-
平臺編號：bio-123148
-
細(xì)胞信息： VAL
-
規(guī)格：1×10?cells/T25培養(yǎng)瓶
-
用途：細(xì)胞系
-
服務(wù)費(fèi)用：
加載中…… - 訂購
-
注意事項(xiàng)：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類或動物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫為準(zhǔn)）
人彌漫性大B細(xì)胞淋巴瘤細(xì)胞
細(xì)胞名稱：人彌漫性大B細(xì)胞淋巴瘤細(xì)胞VAL
產(chǎn)品規(guī)格：T25培養(yǎng)瓶x1；1.5ml凍存管x2
細(xì)胞數(shù)量：1x10^6：1x10^6
保存溫度：37℃；-198℃
運(yùn)輸方式：常溫保溫運(yùn)輸；干冰運(yùn)輸
安全等級：1
用途限制
僅供科研2類培養(yǎng)體系
培養(yǎng)體系DMEM高糖培養(yǎng)基+10%FBS+1%三抗
培養(yǎng)溫度37℃
二氧化碳濃度5%
簡介
人彌漫性大B細(xì)胞淋巴瘤細(xì)胞VAL取自50歲女性骨髓來源。該細(xì)胞源于DSMZ。
注釋
Part of:Cancer Cell Line Encyclopedia(CCLE)project.
Part of:COSMIC cell lines project.
Part of:LL-100 blood cancer cell line panel.
Part of:MD Anderson Cell Lines Project.
Doubling time:~50-70 hours(DSMZ).
Microsatellite instability:Stable(MSS)(Sanger).
Transformant:NCBI_TaxID;10376;Epstein-Barr virus(EBV).
Omics:Array-based CGH.
Omics:Deep exome analysis.
Omics:Deep RNAseq analysis.
Omics:DNA methylation analysis.
Omics:Protein expression by reverse-phase protein arrays.
Omics:Transcriptome analysis.
Miscellaneous:Originally assigned to be from a B-cell acute lymphoblastic leukemia.
Derived from sampling site:Bone marrow.
基因突變
HLA信息
STR信息
Amelogenin X
CSF1PO 10,12
D5S818 11
D7S820 10
D13S317 10,14
D16S539 9,13
TH01 6,9
TPOX 8
vWA 14,15
參考文獻(xiàn)
PubMed=27397505;DOI=10.1016/j.cell.2016.06.017
Iorio F.,Knijnenburg T.A.,Vis D.J.,Bignell G.R.,Menden M.P.,Schubert M.,Aben N.,Goncalves E.,Barthorpe S.,Lightfoot H.,Cokelaer T.,Greninger P.,van Dyk E.,Chang H.,de Silva H.,Heyn H.,Deng X.,Egan R.K.,Liu Q.,Mironenko T.,Mitropoulos X.,Richardson L.,Wang J.,Zhang T.,Moran S.,Sayols S.,Soleimani M.,Tamborero D.,Lopez-Bigas N.,Ross-Macdonald P.,Esteller M.,Gray N.S.,Haber D.A.,Stratton M.R.,Benes C.H.,Wessels L.F.A.,Saez-Rodriguez J.,McDermott U.,Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)
PubMed=28196595;DOI=10.1016/j.ccell.2017.01.005
Li J.,Zhao W.,Akbani R.,Liu W.,Ju Z.,Ling S.,Vellano C.P.,Roebuck P.,Yu Q.,Eterovic A.K.,Byers L.A.,Davies M.A.,Deng W.,Gopal Y.N.V.,Chen G.,von Euw E.M.,Slamon D.J.,Conklin D.,Heymach J.V.,Gazdar A.F.,Minna J.D.,Myers J.N.,Lu Y.,Mills G.B.,Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)
PubMed=30894373;DOI=10.1158/0008-5472.CAN-18-2747
Dutil J.,Chen Z.,Monteiro A.N.,Teer J.K.,Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res.79:1263-1273(2019)
PubMed=31160637;DOI=10.1038/s41598-019-44491-x
Quentmeier H.,Pommerenke C.,Dirks W.G.,Eberth S.,Koeppel M.,MacLeod R.A.F.,Nagel S.,Steube K.,Uphoff C.C.,Drexler H.G.
The LL-100 panel:100 cell lines for blood cancer studies.
Sci.Rep.9:8218-8218(2019)
產(chǎn)品規(guī)格：T25培養(yǎng)瓶x1；1.5ml凍存管x2
細(xì)胞數(shù)量：1x10^6：1x10^6
保存溫度：37℃；-198℃
運(yùn)輸方式：常溫保溫運(yùn)輸；干冰運(yùn)輸
安全等級：1
用途限制
僅供科研2類培養(yǎng)體系
培養(yǎng)體系DMEM高糖培養(yǎng)基+10%FBS+1%三抗
培養(yǎng)溫度37℃
二氧化碳濃度5%
簡介
人彌漫性大B細(xì)胞淋巴瘤細(xì)胞VAL取自50歲女性骨髓來源。該細(xì)胞源于DSMZ。
注釋
Part of:Cancer Cell Line Encyclopedia(CCLE)project.
Part of:COSMIC cell lines project.
Part of:LL-100 blood cancer cell line panel.
Part of:MD Anderson Cell Lines Project.
Doubling time:~50-70 hours(DSMZ).
Microsatellite instability:Stable(MSS)(Sanger).
Transformant:NCBI_TaxID;10376;Epstein-Barr virus(EBV).
Omics:Array-based CGH.
Omics:Deep exome analysis.
Omics:Deep RNAseq analysis.
Omics:DNA methylation analysis.
Omics:Protein expression by reverse-phase protein arrays.
Omics:Transcriptome analysis.
Miscellaneous:Originally assigned to be from a B-cell acute lymphoblastic leukemia.
Derived from sampling site:Bone marrow.
基因突變
HLA信息
STR信息
Amelogenin X
CSF1PO 10,12
D5S818 11
D7S820 10
D13S317 10,14
D16S539 9,13
TH01 6,9
TPOX 8
vWA 14,15
參考文獻(xiàn)
PubMed=27397505;DOI=10.1016/j.cell.2016.06.017
Iorio F.,Knijnenburg T.A.,Vis D.J.,Bignell G.R.,Menden M.P.,Schubert M.,Aben N.,Goncalves E.,Barthorpe S.,Lightfoot H.,Cokelaer T.,Greninger P.,van Dyk E.,Chang H.,de Silva H.,Heyn H.,Deng X.,Egan R.K.,Liu Q.,Mironenko T.,Mitropoulos X.,Richardson L.,Wang J.,Zhang T.,Moran S.,Sayols S.,Soleimani M.,Tamborero D.,Lopez-Bigas N.,Ross-Macdonald P.,Esteller M.,Gray N.S.,Haber D.A.,Stratton M.R.,Benes C.H.,Wessels L.F.A.,Saez-Rodriguez J.,McDermott U.,Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)
PubMed=28196595;DOI=10.1016/j.ccell.2017.01.005
Li J.,Zhao W.,Akbani R.,Liu W.,Ju Z.,Ling S.,Vellano C.P.,Roebuck P.,Yu Q.,Eterovic A.K.,Byers L.A.,Davies M.A.,Deng W.,Gopal Y.N.V.,Chen G.,von Euw E.M.,Slamon D.J.,Conklin D.,Heymach J.V.,Gazdar A.F.,Minna J.D.,Myers J.N.,Lu Y.,Mills G.B.,Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)
PubMed=30894373;DOI=10.1158/0008-5472.CAN-18-2747
Dutil J.,Chen Z.,Monteiro A.N.,Teer J.K.,Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res.79:1263-1273(2019)
PubMed=31160637;DOI=10.1038/s41598-019-44491-x
Quentmeier H.,Pommerenke C.,Dirks W.G.,Eberth S.,Koeppel M.,MacLeod R.A.F.,Nagel S.,Steube K.,Uphoff C.C.,Drexler H.G.
The LL-100 panel:100 cell lines for blood cancer studies.
Sci.Rep.9:8218-8218(2019)
